Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2803-2811

  Winick, N ^a   Shuster, J J ^a   Bowman, W P ^a   Borowitz, M ^a   Farrow, A ^a   Jacaruso, D ^a   Buchanan, G R ^a   Kamen, B A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BRAIN METASTASIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MALE; MYOCARDITIS; NEUROTOXICITY; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME;

EID: 0029739087     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2803     Document Type: Article

References (53)

1. Farber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238:787-793, 1948
2. Pui CH, Simone JV, Hancock ML, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St. Jude total therapy study X. Leukemia 6:150-157, 1992
3. Lauer SJ, Camitta BM, Leventhal BG, et al: Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. Cancer 71:2854-2861, 1993
4. Camitta B, Mahoney D, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T acute lymphocytic leukemia. J Clin Oncol 12:1383-1389, 1994
5. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia. J Clin Oncol 12:1939-1945, 1994
6. Schorin MA, Blattner S, Gelber RD, et al: Treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 12:740-747, 1994
7. Reiter A, Schrappe M, Ludwig W-D, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
8. Spears CP: Clinical resistance to antimetabolites. Hematol Oncol Clin North Am 9:397-413, 1995
9. Dow LW, Chang LJ, Tsiatis AA, et al: Relationship of pretreatment lymphoblast proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia. Blood 59:1197-1202, 1982
10. Look AT, Melvin SL, Williams DL, et al: Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia. Blood 60:959-967, 1982
11. Murphy SB, Dahl GV, George SL, et al: Determination of the significance of in vitro blast cell [3H] thymidine labelling indices obtained initially and serially during induction therapy of acute non-lymphocytic leukemia. Leuk Res 6:639-648, 1982
12. Bokkerink JA, Ronney A: Effects of methotrexate on purine and pyrimidine metabolism and cell kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2329-2338. 1988
13. Rivard GE, Infante-Rivard C, Hoyoux C, et al: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Better in the evening. Lancet 2:1264-1266, 1985
14. Capizzi RL: Schedule dependent synergism and antagonism between methotrexate and asparaginase. Biochem Pharmacol 23:151-161, 1974
15. Capizzi R: Improvement in the therapeutic index of metho trexate (NSC-740) by L-asparaginase (NSC-109229). Cancer Che-mother Rep 6:37-41, 1975
16. Harris RE, McCallister JA, Provisor DS: Methotrexate-L-aspara-ginase combination chemotherapy for patients with acute leukemia in relapse: A study of 36 children. Cancer 46:2004-2008, 1980
17. Capizzi RL: Asparaginase-methotrexate in combination chemotherapy. Schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 65:115-120, 1981
18. Bennett JM, Catovsky D, Daniel MT: Proposals for the classification of the acute leukemias. Br J Haematol 33:451-458, 1976
19. Pui CH, Behm FG, Singh B: Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 75:198-202, 1990
20. Borowitz MJ, Shuster JJ, Civin CI: Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia. J Clin Oncol 8:1389-1398, 1990
21. Winick N, Bowman WP, Kamen BA, et al: Unexpected acute neurologic toxicity in children with acute lymphoblastic leukemia receiving intensive oral methotrexate. J Natl Cancer Inst 84:252-256, 1992
22. Mustafa MM, Pappo A, Cash J, et al: Aerosolized pentamidine for the prevention of pneumocystic carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. J Clin Oncol 12:258-261, 1994
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Peto R, Pike MC, Armitage P: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1-39, 1977
25. Pullen DJ, Boyett JM, Crist WM: Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia (ALL) subgroups. Influence on treatment response. Ann N Y Acad Sci 428:26-48. 1984
26. Winick N, McKenna RW, Shuster JJ: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209-217, 1993
27. Winick N, Bowman W, Arencibia-Mireles O, et al: Prolonged intensive oral methotrexate does not induce its own malabsorption. Cancer Chemother Control 1:245-250, 1990
28. Freeman AI, Weinberg V, Brecher ML: Comparison of inter-mediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphoblastic leukemia in children. N Engl J Med 308:477-484, 1983
29. Green DM, Brecher ML, Blumenson LE: The use of intermediate-dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three vs. six courses. Cancer 50:2722-2727, 1982
30. Borsi JD, Moe PJ: New aspects of clinical and cellular pharmacodynamics of methotrexate with special emphasis on its role in the treatment of acute lymphoblastic leukemia in children. Acta Paediatr Scand 341:1-31, 1987 (suppl)
31. Abromowitch M, Ochs J, Pui CH: Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: Analysis by contemporary risk classification. Blood 71:866-869, 1988
32. Borsi JD, Moe PJ: Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 60:3020-3024, 1987
33. Kamen BA, Winick NJ: High-dose methotrexate: Insecure rationale. Biochem Pharmacol 37:2713-2715, 1988
34. Wolfrom C, Hartmann R, Fengler R, et al: Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 11:827-833, 1993
35. Capizzi R, Cheng Y: Therapy of neoplasia with asparaginase, in Holcenberg J, Roberts J (eds): Enzymes as Drugs. New York, NY, Wiley, 1981, pp 1-24
36. Jolivet J, Cole DE, Holcenberg JS, et al: Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation. Cancer Res 45:217-220, 1985
37. Lobel J, O'Brien R, McIntosh S: Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia in childhood. Cancer 43:1089-1094, 1979
38. Yap B, McCredie KB, Keating MJ: Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 65:83-87, 1981
39. Snyold TW, Relling MV, Boyett JM, et al: Blast cell methotrexate - Polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996-2001, 1994
40. Sirotnak FM, Moccio DM, Dorick DM: Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345-353, 1978
41. Browman GP, Goodyear MDE, Levine MN, et al: Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: A randomized placebo-controlled clinical trial. J Clin Oncol 8:203-208, 1990
42. Thyss A, Milano G, Etienne MC, et al: Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 59:627-630, 1989
43. Kamen BA, Vietti T: Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 60:799, 1989 (letter)
44. Straw JA, Szapary D, Wynn WT: Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114-3119, 1984
45. Straw JA, Newman EM, Doroshow JH: Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. NCI Monogr 5:41-45, 1987
46. Borsi JD, Wesenberg F, Stokland T, et al: How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 27:1006-1009, 1991
47. Pui CH, Ribeiro RC, Hancock ML: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682-1687, 1991
48. Lorico A, Rappa G, Boiocchi M: Increase in etoposide-induced topoisomerase H-mediated DNA breaks after cell synchronization induced by low doses of methotrexate. Biochem Pharmacol 37:1883-1884, 1988
49. Holden SA, Teicher BA, Robinson MF, et al: Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother Pharmacol 36:165-171, 1995
50. Pui CH, Relling MV, Behm FG, et al: L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 9:1680-1684, 1995
51. Winick N, Buchanan GR, Kamen BA: Secondary acute myeloid leukemia in Hispanic children. J Clin Oncol 11:1433, 1993 (letter)
52. Ross JA, Potter JD, Robison LL: Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Nat Cancer Inst 86:1678-1680, 1994
53. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 345:143-148, 1995